Esco Aster
Singapore, Singapore· Est.
Integrated CDMO delivering cGMP‑grade vaccines, cell‑therapies and cultivated meat via proprietary packed‑bed bioreactors.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Integrated CDMO delivering cGMP‑grade vaccines, cell‑therapies and cultivated meat via proprietary packed‑bed bioreactors.
VaccinesCell TherapyGene TherapyOncologyRegenerative MedicineDiagnosticsNutraceuticals
Technology Platform
Proprietary single‑use adherent packed‑bed bioreactor (Tide Motion) combined with continuous flow chemistry and cGMP‑compliant process development for scalable manufacturing of vaccines, cell‑therapies and cultivated meat.
Opportunities
Expansion of cultivated meat production and scaling of cell‑therapy manufacturing platforms to serve emerging‑market vaccine and regenerative‑medicine demand.
Risk Factors
Regulatory uncertainty for cell‑based foods, technical challenges of large‑scale adherent cell culture, and competition from larger, well‑funded CDMOs.
Competitive Landscape
Competes with established CDMOs such as Lonza, Catalent, and Samsung Biologics, differentiating through its patented packed‑bed bioreactor and first‑mover status in cultivated meat manufacturing.